Cargando…

Heterogeneity of white adipocytes in metabolic disease

This review aims to discuss the most recent evidence identifying the presence of distinct white adipocyte subpopulations in white adipose tissue (WAT) and how these may be altered with increasing adiposity and/or metabolic disease. We conceptualize how changes in adipocyte subpopulations may contrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilson, Josh, Sethi, Jaswinder K., Byrne, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894153/
https://www.ncbi.nlm.nih.gov/pubmed/36728211
http://dx.doi.org/10.1097/MCO.0000000000000885
_version_ 1784881682198822912
author Bilson, Josh
Sethi, Jaswinder K.
Byrne, Christopher D.
author_facet Bilson, Josh
Sethi, Jaswinder K.
Byrne, Christopher D.
author_sort Bilson, Josh
collection PubMed
description This review aims to discuss the most recent evidence identifying the presence of distinct white adipocyte subpopulations in white adipose tissue (WAT) and how these may be altered with increasing adiposity and/or metabolic disease. We conceptualize how changes in adipocyte subpopulations may contribute to alterations in WAT function and the development of metabolic diseases such as type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). RECENT FINDINGS: Studies utilizing novel analytical approaches support the existence of distinct white adipocyte subpopulations in both human and murine WAT. Adipocyte subtypes are potentially functionally distinct and may have different roles in WAT function and obesity-associated metabolic diseases. SUMMARY: The exploration of white adipocyte heterogeneity using novel analytical technologies, has unveiled a new layer of complexity in the study of WAT biology. Interrogation of potential functional differences between adipocyte subpopulations and their role in the function of different WAT depots is now needed. Through understanding the mechanisms regulating white adipocyte subtype development and potential pathophysiological consequences of changes in the presence of adipocyte subpopulations, studies could provide novel therapeutic targets for the treatment of T2DM, NAFLD, and CVD.
format Online
Article
Text
id pubmed-9894153
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98941532023-02-07 Heterogeneity of white adipocytes in metabolic disease Bilson, Josh Sethi, Jaswinder K. Byrne, Christopher D. Curr Opin Clin Nutr Metab Care LIPID METABOLISM AND THERAPY: Edited by Philip C. Calder and William Harris This review aims to discuss the most recent evidence identifying the presence of distinct white adipocyte subpopulations in white adipose tissue (WAT) and how these may be altered with increasing adiposity and/or metabolic disease. We conceptualize how changes in adipocyte subpopulations may contribute to alterations in WAT function and the development of metabolic diseases such as type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). RECENT FINDINGS: Studies utilizing novel analytical approaches support the existence of distinct white adipocyte subpopulations in both human and murine WAT. Adipocyte subtypes are potentially functionally distinct and may have different roles in WAT function and obesity-associated metabolic diseases. SUMMARY: The exploration of white adipocyte heterogeneity using novel analytical technologies, has unveiled a new layer of complexity in the study of WAT biology. Interrogation of potential functional differences between adipocyte subpopulations and their role in the function of different WAT depots is now needed. Through understanding the mechanisms regulating white adipocyte subtype development and potential pathophysiological consequences of changes in the presence of adipocyte subpopulations, studies could provide novel therapeutic targets for the treatment of T2DM, NAFLD, and CVD. Lippincott Williams & Wilkins 2023-03 2023-01-11 /pmc/articles/PMC9894153/ /pubmed/36728211 http://dx.doi.org/10.1097/MCO.0000000000000885 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle LIPID METABOLISM AND THERAPY: Edited by Philip C. Calder and William Harris
Bilson, Josh
Sethi, Jaswinder K.
Byrne, Christopher D.
Heterogeneity of white adipocytes in metabolic disease
title Heterogeneity of white adipocytes in metabolic disease
title_full Heterogeneity of white adipocytes in metabolic disease
title_fullStr Heterogeneity of white adipocytes in metabolic disease
title_full_unstemmed Heterogeneity of white adipocytes in metabolic disease
title_short Heterogeneity of white adipocytes in metabolic disease
title_sort heterogeneity of white adipocytes in metabolic disease
topic LIPID METABOLISM AND THERAPY: Edited by Philip C. Calder and William Harris
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894153/
https://www.ncbi.nlm.nih.gov/pubmed/36728211
http://dx.doi.org/10.1097/MCO.0000000000000885
work_keys_str_mv AT bilsonjosh heterogeneityofwhiteadipocytesinmetabolicdisease
AT sethijaswinderk heterogeneityofwhiteadipocytesinmetabolicdisease
AT byrnechristopherd heterogeneityofwhiteadipocytesinmetabolicdisease